@article{3ba7b6b7640f4adbad70a333f66fed57,
title = "Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version)",
abstract = "Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies, such as radiofrequency ablation or transarterial chemoembolization. Therefore, establishment of response evaluation criteria solely devoted to HCC is needed in clinical practice, as well as in clinical trials of HCC treatment, such as systemic therapies, which cause necrosis of the tumor. Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2021 by the Liver Cancer Study Group of Japan based on the 2019 version of RECICL, which was commonly used in Japan. The major revised points of the RECICL 2021 is inclusion of RECIST version 1.1 and modified RECIST as response evaluation criteria in systemic therapy for HCC. We hope this new treatment response criteria, RECICL, proposed by the Liver Cancer Study Group of Japan will benefit the HCC treatment response evaluation in the setting of daily clinical practice and clinical trials as well, not only in Japan, but also internationally.",
keywords = "Liver Cancer Study Group of Japan, hepatocellular carcinoma, modified RECIST, response evaluation criteria in cancer of the liver (RECICL), response evaluation criteria in solid tumors (RECIST)",
author = "Masatoshi Kudo and Masafumi Ikeda and Kazuomi Ueshima and Michiie Sakamoto and Shuichiro Shiina and Ryosuke Tateishi and Kazuhiro Nouso and Kiyoshi Hasegawa and Junji Furuse and Shiro Miyayama and Takamichi Murakami and Tatsuya Yamashita and Norihiro Kokudo",
note = "Funding Information: Masatoshi Kudo: Honoraria from Eisai, Bayer, MSD, BMS, EA Pharma, Eli Lilly, Chugai. Consulting or advisory role for Eisai, Ono Pharmaceutical Co, MSD, BMS, Roche. Research funding from Eisai, Takeda, Otsuka, Taiho, EA Pharma, Gilead Sciences, Abbvie, Sumitomo Dainippon Pharma, Chugai, Ono Pharmaceutical Co. Funding Information: Masafumi Ikeda: Honoraria from Bayer, Chugai, Eisai, Eli Lilly Japan, Takeda. Research funding from Bayer, Eisai, Bristol Myers Squibb, AstraZeneca, Chugai, Merck Serono, MSD, Takeda. Funding Information: Michiie Sakamoto: Research funding from Eisai, Cytlimic. Publisher Copyright: {\textcopyright} 2022 The Authors. Hepatology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Hepatology.",
year = "2022",
month = apr,
doi = "10.1111/hepr.13746",
language = "English",
volume = "52",
pages = "329--336",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "4",
}
